Note: Ingredients listed on restricted chemical lists
EC/CAS
7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
80 - 100
EC/CAS
50-70-4
Name of the chemical
D-glucitol C6H14O6
Concentration
1-5
EC/CAS
1310-73-2
Name of the chemical
Potassium or sodium hydroxide (20)
Concentration
<0.1
EC/CAS
7647-01-0
Name of the chemical
Hydrochloric acid
Concentration
<0.1
EC/CAS
77-92-9
Name of the chemical
Citric acid
Concentration
<0.1
General Information
Version
1.0
Revision date
2025-03-24
Product name
Diltiazem Hydrochloride in 0.72% Sodium Chloride Injection
1.2.1 Relevant identified uses
Treatment of high blood pressure (hypertension), angina
1.2.2. Uses advised against
No additional information available
Emergency telephone
+1-866-562-4708
Icons in SDS
Company Information
company name
WG Critical Care, LLC
e-mail address of the competent person responsible for the Safety Data Sheet
wgccquality@wgcriticalcare.com
Hazard Codes
Hazard statements (CLP)
H362
Hazard statements
Code
Statements
H362
May cause harm to breast-fed children
Section 2
SECTION 2: Hazards identification
Classification of the Substance or Mixture GHS-US Classification Reproductive toxicity, Additional category, Effects on or via lactation H362
2.2 Label elements
GHS-US Labeling
Hazard statements
H362 - May cause harm to breast-fed children.
Precautionary statements
P201 - Obtain special instructions before use. P202 - Do not handle until all safety precautions have been read and understood. P260 - Do not breathe mist, spray, vapors. P263 - Avoid contact during pregnancy and while nursing. P264 - Wash hands, forearms and face thoroughly after handling. P270 - Do not eat, drink or smoke when using this product. P308+P313 - If exposed or concerned: Get medical advice/attention. 2.3 Hazards associated with known or reasonably anticipated uses This product is a pharmaceutical product designed for administration to a patient by a qualified medical professional. No other uses are anticipated. A Process Hazard Analysis (PHA) or other hazard assessment for additional specific end uses should be performed to ensure that hazards are fully understood, and adequate safety measures are in place. See Section 10 for relevant reactivity and stability information.
2.3 Other hazards
Exposure may aggravate pre-existing eye, skin, or respiratory conditions.
Ingredient(s) with unknown acute toxicity
Dermal and Inhalative toxicity is unknown, but is not expected to be hazardous.
2.1 Classification of the substance or mixture
GHS-US Classification Reproductive toxicity, Additional category, Effects on or via lactation H362